弥散加权磁共振成像评估弥漫性肾脏病理:系统综述与声明文件
本文系统综述了肾脏弥散加权磁共振成像(DWI)在弥漫性肾脏疾病中的应用现状。DWI 生物标志物可分为表观弥散系数、真实弥散/假弥散/流动分数和分数各向异性三类,人研究显示其可行性及研究内可重复性,但需标准化和验证。作为 COST PARENCHIMA 行动的一部分,文章为未来临床研究设计和临床实践提供实用建议。
要点
- DWI 生物标志物分三类:ADC、真实弥散/假弥散/流动分数、分数各向异性。
- DWI 有望作为 CKD 间质纤维化的替代和监测生物标志物。
- DWI 可能作为急性肾疾病炎症的替代标志物,影响肾活检选择。
核心结论
- 肾脏 DWI 在弥漫性肾脏疾病中可行且研究内可重复,但需方法标准化和验证。
- DWI 有潜力作为 CKD 间质纤维化的替代和监测生物标志物。
- DWI 可能作为急性肾疾病炎症的替代标志物,影响急性移植物排斥的肾活检选择。
研究设计与样本
- 系统综述,纳入应用肾脏 DWI 于弥漫性病理的人研究。
- 作为 COST PARENCHIMA 行动的一部分,提供未来研究设计和临床实践建议。
主要发现
- DWI 生物标志物分为表观弥散系数、真实弥散/假弥散/流动分数和分数各向异性三类。
- 人研究显示 DWI 的可行性和研究内可重复性。
- 强调需要标准化方法、额外验证和资格认定。
临床怎么用
- DWI 可作为 CKD 间质纤维化的替代和监测生物标志物。
- DWI 可作为急性肾疾病炎症的替代标志物,可能影响急性移植物排斥的肾活检选择。
- 文章提供未来临床研究设计和肾脏 DWI 临床使用的实用建议。
局限性
- 需要标准化方法、额外验证和资格认定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffusion-weighted magnetic resonance imaging (DWI) is a non-invasive method sensitive to local water motion in the tissue. As a tool to probe the microstructure, including the presence and potentially the degree of renal fibrosis, DWI has the potential to become an effective imaging biomarker. The aim of this review is to discuss the current status of renal DWI in diffuse renal diseases. DWI biomarkers can be classified in the following three main categories: (i) the apparent diffusion coefficient-an overall measure of water diffusion and microcirculation in the tissue; (ii) true diffusion, pseudodiffusion and flowing fraction-providing separate information on diffusion and perfusion or tubular flow; and (iii) fractional anisotropy-measuring the microstructural orientation. An overview of human studies applying renal DWI in diffuse pathologies is given, demonstrating not only the feasibility and intra-study reproducibility of DWI but also highlighting the need for standardization of methods, additional validation and qualification. The current and future role of renal DWI in clinical practice is reviewed, emphasizing its potential as a surrogate and monitoring biomarker for interstitial fibrosis in chronic kidney disease, as well as a surrogate biomarker for the inflammation in acute kidney diseases that may impact patient selection for renal biopsy in acute graft rejection. As part of the international COST (European Cooperation in Science and Technology) action PARENCHIMA (Magnetic Resonance Imaging Biomarkers for Chronic Kidney Disease), aimed at eliminating the barriers to the clinical use of functional renal magnetic resonance imaging, this article provides practical recommendations for future design of clinical studies and the use of renal DWI in clinical practice.
引用
- Caroli A, Schneider M, Friedli I, et al. Diffusion-weighted magnetic resonance imaging to assess diffuse renal pathology: a systematic review and statement paper. Nephrol Dial Transplant. 2018. PMID: 30137580. doi:10.1093/ndt/gfy163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。